# Vividion Therapeutics

Vividion Therapeutics is an Asset Manager based in San Diego, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** San Diego, United States
- **Region:** North America
- **Address:** San Diego, CA, United States
- **Assets under management:** Undisclosed
- **Website:** www.vividion.com
- **LinkedIn:** https://www.linkedin.com/company/vividion-therapeutics

## Regulatory record

- **Reports private funds:** No

## About

We are bringing more disease-causing targets within the reach of small molecule therapeutics to transform care for patients with devastating diseases not

## Sectors

- Biotechnology
- Oncology

## Questions

### What is VVD-214 and why does its mechanism matter?

VVD-214 is a covalent allosteric inhibitor of the WRN helicase. WRN is a synthetic-lethal target in microsatellite-instability-high tumors, meaning cancer cells that rely on WRN for survival cannot compensate when the protein is blocked. Vividion published the discovery and preclinical characterization of VVD-214 in January 2026, confirming its clinical-stage advancement (per Journal of Medicinal Chemistry, 2026). Allosteric inhibition offers a selectivity advantage over orthosteric approaches, reducing off-target toxicity in a target class where ATP-competitive inhibitors have historically struggled.

## Related profiles

- [Tri Locum Partners](https://altss.com/profile/tri-locum-partners)
- [Novo Nordisk](https://altss.com/profile/novo-nordisk-as)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/vividion-therapeutics

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology